We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mead Johnson Nutrition Company (delisted) | NYSE:MJN | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 89.98 | 0 | 01:00:00 |
By Lisa Beilfuss
Mead Johnson Nutrition Co. said first-quarter profit rose 2.5%, though revenue slipped and the company trimmed its sales growth expectation for the year amid unfavorable currency rates.
Illinois-based Mead Johnson, which sells baby formula and children's nutritional products, warned earlier this year it faced significant headwinds from the strengthening dollar.
"With over 70% of our business outside the United States, foreign currency translation negatively impacted our topline," Chief Executive Kasper Jakobsen said Thursday. While most of Mead Johnson's revenue is denominated in foreign currencies, much of its costs are in U.S. dollars.
In all, Mead Johnson reported a profit of $207.4 million, or $1.02 a share, up from $202.4 million, or $1 per share, a year earlier. Excluding items, including currency fluctuations, per-share profit rose to $1.09 a share from $1.02.
Higher gross margins, lower operating expenses and a lower tax rate were the main drivers of earnings growth, the company said.
Revenue declined 1.7% to $1.09 billion.
Analysts were looking for $1.05 in profit per share on $1.113 billion in revenue
For the full year, the company continues to project $3.90 to $4 in adjusted per-share profit, but it trimmed its sales growth estimate to 2% from 3% because of foreign-exchange impact.
Analysts are looking for a full-year profit of $4 a share on $4.55 billion in revenue.
Gross margin improved to 64% from 63.6% in the first quarter, as the company benefited from price increases and lower dairy costs.
On a currency adjusted basis, sales in the company's North America and Europe segment rose 3%, Latin America sales jumped 13% and Asia sales were flat from a year earlier.
Access Investor Kit for Bristol-Myers Squibb Co.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US1101221083
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Morgan Stanley DW Str Sat Att Chart |
1 Month Morgan Stanley DW Str Sat Att Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions